New CAR-T Therapy Avoids Chemo for Cancer Patients

An innovative CAR-T cell therapy, utilizing T memory stem cells, may allow blood cancer patients to bypass the need for standard, toxic chemotherapy. Initial findings from a Phase 1 trial suggest this modified approach can lead to higher complete response rates in patients, with some experiencing long-term disease remission without preconditioning chemotherapy.

This CAR-T variant demonstrated faster multiplication and longer function compared to traditional CAR-T cells. Patients treated with the memory stem cell therapy also experienced a lower incidence of a common inflammatory reaction, indicating a potentially safer profile.

Separately, a groundbreaking application of artificial intelligence in a simple finger-cuff device shows promise for equitable heart disease diagnosis. The AI algorithm accurately detects moderate-to-severe aortic stenosis in Black patients, who are disproportionately affected by this condition and often underdiagnosed.

This accessible screening method achieved 100% accuracy in identifying the disease among Black participants in the study. Researchers believe this technology can significantly improve early diagnosis and treatment access for underserved communities.